Literature DB >> 18444918

Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study.

T S Dabade1, J P Grande, S M Norby, F C Fervenza, F G Cosio.   

Abstract

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. MN can recur after kidney transplantation causing proteinuria, allograft dysfunction and graft failure. In this study we assessed the incidence of MN recurrence utilizing surveillance graft biopsies. The study included 1310 renal allograft recipients from 2000 to 2006. Glomerular diseases were the cause of kidney failure in 28% of patients and 23 (2%) had idiopathic MN. Recurrent MN was diagnosed in eight of 19 patients included in this analysis (42%) 13 +/- 20 months (median = 4; range 2-61 months) after transplant. The initial clinical manifestations of recurrent MN were mild or absent. Urine protein excretion was 825 +/- 959 (64-2286) mg/day and three patients had no proteinuria. Five of seven patients who did not receive additional immunosuppression for MN had significant increases in proteinuria during follow up and three became nephrotic. At diagnosis, light microscopic changes were subtle or absent. All patients had granular glomerular basement membrane deposits of IgG but little or absent C3 by immunofluorescence. Subepithelial deposits were observed in all cases by electron microscopy. In conclusion, idiopathic MN recurred in 42% of patients after transplantation. The initial clinical and histologic manifestations are subtle but the disease is progressive.

Entities:  

Mesh:

Year:  2008        PMID: 18444918     DOI: 10.1111/j.1600-6143.2008.02237.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  20 in total

Review 1.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 2.  Membranous Nephropathy: A Journey From Bench to Bedside.

Authors:  Jean M Francis; Laurence H Beck; David J Salant
Journal:  Am J Kidney Dis       Date:  2016-04-13       Impact factor: 8.860

3.  Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation.

Authors:  Ben Sprangers; George Ian Lefkowitz; Scott D Cohen; Michael Barry Stokes; Antony Valeri; Gerald B Appel; Cheryl L Kunis
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

Review 4.  A Proposal for a Serology-Based Approach to Membranous Nephropathy.

Authors:  An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 10.121

Review 5.  Immunopathogenesis of membranous nephropathy: an update.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Semin Immunopathol       Date:  2014-04-09       Impact factor: 9.623

Review 6.  Primary Membranous Nephropathy.

Authors:  William G Couser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-26       Impact factor: 8.237

7.  Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.

Authors:  A Kattah; R Ayalon; L H Beck; S Sethi; D G Sandor; F G Cosio; M J Gandhi; E C Lorenz; D J Salant; F C Fervenza
Journal:  Am J Transplant       Date:  2015-03-12       Impact factor: 8.086

Review 8.  Membranous nephropathy: from models to man.

Authors:  Laurence H Beck; David J Salant
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 9.  The role of complement in membranous nephropathy.

Authors:  Hong Ma; Dana G Sandor; Laurence H Beck
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

10.  Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir).

Authors:  Naoka Murakami; Yanli Ding; David J Cohen; Anil K Chandraker; Helmut G Rennke
Journal:  Transpl Infect Dis       Date:  2018-07-23       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.